[go: up one dir, main page]

PT3634428T - Medicamento para prevenção ou tratamento de infeção por rinovírus - Google Patents

Medicamento para prevenção ou tratamento de infeção por rinovírus

Info

Publication number
PT3634428T
PT3634428T PT188330690T PT18833069T PT3634428T PT 3634428 T PT3634428 T PT 3634428T PT 188330690 T PT188330690 T PT 188330690T PT 18833069 T PT18833069 T PT 18833069T PT 3634428 T PT3634428 T PT 3634428T
Authority
PT
Portugal
Prior art keywords
drug
prevention
treatment
rhinovirus infection
rhinovirus
Prior art date
Application number
PT188330690T
Other languages
English (en)
Original Assignee
Univ Wien Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med filed Critical Univ Wien Med
Publication of PT3634428T publication Critical patent/PT3634428T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT188330690T 2018-01-30 2018-12-28 Medicamento para prevenção ou tratamento de infeção por rinovírus PT3634428T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18154088.1A EP3517117A1 (en) 2018-01-30 2018-01-30 Medicament for prevention or treatment of rhinovirus infection

Publications (1)

Publication Number Publication Date
PT3634428T true PT3634428T (pt) 2022-03-22

Family

ID=61094293

Family Applications (1)

Application Number Title Priority Date Filing Date
PT188330690T PT3634428T (pt) 2018-01-30 2018-12-28 Medicamento para prevenção ou tratamento de infeção por rinovírus

Country Status (13)

Country Link
US (4) US11413298B2 (pt)
EP (4) EP3517117A1 (pt)
JP (3) JP7359519B2 (pt)
CN (3) CN111655267B (pt)
AU (1) AU2018406914B2 (pt)
BR (1) BR112020012869A2 (pt)
CA (1) CA3086085A1 (pt)
EA (1) EA202091199A1 (pt)
ES (2) ES2989664T3 (pt)
HU (1) HUE058250T2 (pt)
PL (1) PL3634428T3 (pt)
PT (1) PT3634428T (pt)
WO (1) WO2019149436A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515601A (zh) * 2020-03-16 2022-12-23 得克萨斯大学体系董事会 用己糖型单糖及其类似物治疗病毒感染的方法
EP4132464A1 (en) * 2020-04-11 2023-02-15 Exploration Invest Pte Ltd 2-deoxy-d-glucose for prevention and treatment of a viral disease, in particular of covid-19
EP4188984A1 (en) 2020-07-30 2023-06-07 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compositions and use thereof
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2577321A (en) 1949-10-29 1951-12-04 Joseph B Filger Nose drop dispenser
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4603122A (en) * 1979-08-17 1986-07-29 Blough Herbert A Antiviral agent against herpes virus infections
EP0169146A3 (en) * 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
DE8422872U1 (de) 1984-08-01 1984-10-25 Anasco GmbH, 6200 Wiesbaden Spender zur intranasalen applikation von fluessigkeiten in form von sprays oder tropfen
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US6000580A (en) 1992-06-03 1999-12-14 Astra Aktielbolag Device for dispensing preservative-free nasal sprays and similar preparations
DE19706489C2 (de) * 1997-02-19 2000-08-31 Deutsches Krebsforsch Verwendung von 2-Desoxyglucose zur Behandlung von Human-Papilloma-Virus-assoziierten Läsionen und/oder Neoplasien
CA2238460A1 (en) * 1997-05-23 1998-11-23 Imutec Pharma Inc. Immunomodulating compositions for the treatment of viral disorders
US6260549B1 (en) 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
AU2003261475B2 (en) * 1998-11-05 2006-10-26 Centre National De La Recherche Scientifique Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection
ES2375333T3 (es) 2001-03-20 2012-02-28 Trudell Medical International Aparato nebulizador.
CA2703585A1 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
EP2633864A1 (en) * 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
AU2009274508A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
ES2692377T3 (es) * 2009-10-22 2018-12-03 Propanc Pty Ltd Composición farmacéutica para tratar el cáncer que comprende tripsinógeno y quimotripsinógeno
CN102178686B (zh) * 2010-01-07 2016-01-13 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
US8633165B2 (en) * 2010-08-04 2014-01-21 Wisconsin Alumni Research Foundation Neuroprotective effects of 2DG in traumatic brain injury
WO2012077828A1 (ja) * 2010-12-08 2012-06-14 学校法人日本医科大学 炎症性サイトカインの機能を抑制する炎症性疾患治療剤
EP2782585B1 (en) * 2011-11-23 2018-12-26 3B Pharmaceuticals, Inc. Antiviral formulations
EP3328376A4 (en) * 2015-07-31 2019-03-13 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
US10813893B2 (en) * 2017-02-24 2020-10-27 Cellular Sciences, Inc. Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea

Also Published As

Publication number Publication date
EP4487853A1 (en) 2025-01-08
US20240316082A1 (en) 2024-09-26
JP2021516219A (ja) 2021-07-01
EP3634428B1 (en) 2022-01-26
AU2018406914A1 (en) 2020-07-02
HUE058250T2 (hu) 2022-07-28
CA3086085A1 (en) 2019-08-08
ES2907138T3 (es) 2022-04-22
BR112020012869A2 (pt) 2020-12-29
US20220362272A1 (en) 2022-11-17
EP3988102B1 (en) 2024-09-18
US11413298B2 (en) 2022-08-16
CN116459265A (zh) 2023-07-21
EP3517117A1 (en) 2019-07-31
EP3634428A1 (en) 2020-04-15
ES2989664T3 (es) 2024-11-27
US20240316083A1 (en) 2024-09-26
JP2023134592A (ja) 2023-09-27
WO2019149436A1 (en) 2019-08-08
CN111655267B (zh) 2023-06-20
CN116473982A (zh) 2023-07-25
AU2018406914B2 (en) 2024-12-19
JP2023134593A (ja) 2023-09-27
JP7359519B2 (ja) 2023-10-11
US12011453B2 (en) 2024-06-18
US20200397805A1 (en) 2020-12-24
EP3988102A1 (en) 2022-04-27
EP3988102C0 (en) 2024-09-18
CN111655267A (zh) 2020-09-11
EA202091199A1 (ru) 2020-10-19
PL3634428T3 (pl) 2022-03-14

Similar Documents

Publication Publication Date Title
CY2022039I1 (el) Θεραπευτικες ενωσεις χρησιμες για την προφυλακτικη ή θεραπευτικη αγωγη μολυνσης ιου ηiv
EP3589287A4 (en) MACROCYCLIC COMPOUNDS INTENDED FOR THE TREATMENT OF MEDICAL CONDITIONS
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
EP3813808A4 (en) Methods of treating substance abuse
EP3622407A4 (en) Patient treatment systems and methods
HUE056608T2 (hu) Trispecifikus és/vagy trivalens kötõfehérjék HIV-fertõzés megelõzésére vagy kezelésére
PT3634428T (pt) Medicamento para prevenção ou tratamento de infeção por rinovírus
EP3691639A4 (en) MONOBACTAM CHROMANE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
HUE053944T2 (hu) 7-Szubsztituált szulfonimidoilpurinon vegyületek vírusfertõzés kezelésére és megelõzésére
EP3766497A4 (en) Drug for treating cough
HUE067057T2 (hu) Gyógyszerkészítmény C5-tel kapcsolatos betegség kezelésében vagy megelõzésében történõ alkalmazásra
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
DK3558335T3 (da) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
HUE064253T2 (hu) Emulziók hüvelyi fertõzések kezelésére
ES1226210Y (es) Dispositivo de plasma físico para desinfección de heridas cutáneas
EP3714885A4 (en) COMPOSITION FOR PREVENTING, RELIEVING OR TREATING DISEASES OF BONE LOSS, INCLUDING CYCLO (HIS-PRO) (CHP)
ZA201805408B (en) Medicament for treatment of diabetic foot infections
MA49040A (fr) Procédés de prévention ou de traitement de maladies ophtalmiques
PT3290051T (pt) Composição farmacêutica para o tratamento e/ou prevenção de cancro
EP3846803A4 (en) Macrocyclic compounds for the treatment of medical disorders
FR3032616B1 (fr) Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
EP3706867A4 (en) POLYTHERAPIES FOR THE TREATMENT OF CEREBELLOUS ATAXIA
BR112018005305A2 (pt) agente profilático ou terapêutico da queratite fungal
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
EP3829559A4 (en) HISTONE DEACETYLASE INHIBITORS USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION